mcafee internet security 2017 at london drugs

Represented Celgene Corporation, a global biotechnology company, in connection with various strategic partnerships.Represented Gilead Sciences in connection with various collaboration agreements, including with Nurix Therapeutics to discover targeted protein degradation drugs for the treatment of cancer.Represented Johnson & Johnson in connection with various licensing and collaboration agreements with biotechnology and consumer product companies.

Life Sciences Collaborations and Licensing

Megan also regularly represents companies and private equity firms on IP and technology strategy and structuring for mergers and acquisitions as well as data use, digital health, social media, and marketing issues. Megan represents companies in the life sciences, technology, health care, media, software, and branded products industries. These transactions include collaborations, licensing, joint ventures, and complex commercial arrangements for research, development, supply, distribution, promotion, outsourcing, and other relationships. With a background in computer science, Megan advises companies, investors, and universities in strategic transactions involving valuable IP or technology assets. Megan is also managing partner of the firm's Silicon Valley office and a co-head of the Digital Health Initiative. Megan is a partner in Ropes & Gray’s intellectual property transactions, life sciences, and technology, media & telecommunications practice groups.

Mcafee internet security 2017 at london drugs